Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hidden killers in controlled hypertension: study probes why blood pressure meds aren't enough

NCT ID NCT07187596

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study combines data from over 2,500 people with treated and controlled high blood pressure to understand why some still die from heart attacks, strokes, or kidney failure. Researchers are looking beyond blood pressure numbers to find other factors that might predict these fatal outcomes. The goal is to improve how we manage hypertension and prevent unexpected deaths.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify hidden risk factors that cause death even when blood pressure is controlled, leading to better monitoring or treatment strategies.
What could go wrong
This is a pooled analysis of existing studies, not a new treatment trial. It may not find clear answers, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,547 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Studies including patients (any age or sex) with: * Interventional treatment for hypertension * Documented blood pressure control (as defined by each primary study) * Reported mortality or fatal outcome

Ages

1 minute to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion: * Human birth in all sex chromosomes. * Study reports evidence of living with owned systemic/arterial hypertension by one of definition following; * Quantitative: Blood pressure number higher over the normal range by each protocol in mmHg unit in any arm of study. * Qualitative: Clarify the underwent both retrospective, observation or intervention of blood pressure and clearly clarify number of hypertension participants in article. * Study design: any type of studies and have a doi number. * In case report type study, the article recruit in only high blood pressure is a burden that reports both direct intervention for blood pressure or indirect intervention such as treatment of vascular damage from high blood pressure. * In a group of literature review type study, the number of hypertension participants with references from both in supplementary document or traced back via each doi number have to clearly declare in that free full-text and currently non-retracted article without personal requirement as raw material to processing the individual participant data meta-analysis * Study recruit only last version of study series that have to confirm published the hypertension participant with mortality outcomes. * English-language studies. * Exclusion: * Non human/human-specimen studies. * Evidence confirms local site or specific system hypertension only such as studies of pulmonary hypertension, portal hypertension, ocular hypertension without clearly defining the number of systemic arterial hypertension in articles. * No report of conclusion of participant such as no mortality report, no failed/successful outcome from last follow up from hypertension associated life-threatening event. * Deaths due to suicide, trauma, or illegal drugs including intend to take medication overdose in any reason. * Book, Testimonial, Interview, Conference, Protocol articles. * Sub-group analysis. * Duplicate one of the doi/nct/prospero numbers. * No doi. Number

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial aneurysm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Owned study

    Bangkok, Bangkok, 10110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.